Open AccessOR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
Author(s) -
Maria E. Cabanillas,
Naifa L. Busaidy,
Ramona Dadu,
Renata Ferrarotto,
Neil D. Gross,
Maria Gule-Monroe,
Charles Lu,
Horiana B. Grosu,
Michelle D. Williams,
Mark Zafereo
Publication year - 2019
Publication title -
journal of the endocrine society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.046
H-Index - 20
ISSN - 2472-1972
DOI - 10.1210/js.2019-or27-6
Subject(s) - medicine , vemurafenib , trametinib , cohort , dabrafenib , atezolizumab , oncology , everolimus , mek inhibitor , regimen , kras , anaplastic thyroid cancer , thyroid cancer , surgery , cancer , colorectal cancer , pembrolizumab , kinase , immunotherapy , mapk/erk pathway , metastatic melanoma , biology , microbiology and biotechnology